From Innovation to Implementation
The Manalis lab at MIT developed the Suspended Microchannel Resonator (SMR) to measure the weight of individual cells. Exclusively Travera uses this breakthrough technology to measure the growth response of live cancer cells.
Since 2018, multiple clinical studies at prominent academic medical institutions in the United States gathered clinical evidence for the accuracy of our rapid therapy selection testing process.
Travera's CLIA-certified Laboratory Developed Tests (LDTs) currently span virtually all cancer drugs (immunotherapies, targeted inhibitors, cytotoxics, etc.).
